When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
NEW YORK (Reuters Health) – Allogeneic blood transfusions in patients who undergo coronary artery bypass graft surgery (CABG) substantially increase the patient’s odds of nosocomial infection, hospital readmission…
E. Murat Tuzcu, MD, Professor of Medicine, Cleveland Clinic, discusses percutaneous mitral valve replacement, which is more challenging than aortic valve replacement, using a mitral valve clip called…
E. Murat Tuzcu, MD, Professor of Medicine, Cleveland Clinic, discusses catheter-based aortic valve replacement and the Partner trial, which is studying the outcomes of surgery versus catheter or…
E. Murat Tuzcu, MD, Professor of Medicine, Cleveland Clinic, discusses anticoagulation for patients with mechanical valves, highlighting the use of the antithrombotics aspirin and clopidogrel for some patients…
NEW YORK (Reuters Health) – Use of metformin is associated with a decreased risk of pancreatic cancer in patients with diabetes, new research shows. By contrast, treatment with…
Welcome to the world’s first film festival dedicated to raising awareness about the impact of prostate cancer on the ‘whole man’ mind, body and spirit. Being diagnosed with…
NEW YORK (Reuters Health) – New research suggests that the routine use of MRI for newly diagnosed breast cancer does not improve margin status or attempts at breast-conserving…
NEW YORK (Reuters Health) – In patients with metastatic renal cell carcinoma, first-line treatment with interferon (IFN)-alpha plus sunitinib or bevacizumab has “clinically relevant and statistically significant” survival…
NEW YORK (Reuters Health) – Adding hormone therapy to radiotherapy for locally advanced prostate cancer reduces disease recurrence and prolongs survival, according to a report in the August…
Robert Shorr, Ph.D, D.I.C, Chief Executive Officer of Cornerstone Pharmaceuticals, talks about his company’s approach to the treatment of cancer by targeting and exploiting specific metabolic pathways with…
